SOURCE: MEDX Health Corp.

MedX Health Corp.

December 31, 2015 18:26 ET

MedX Health Corp. Announces Issuance of Shares and Share Option Grant

MISSISSAUGA, ON--(Marketwired - December 31, 2015) - MedX Health Corp. ("MedX" or the "Company") (TSX VENTURE: MDX) announces that, effective December 23, 2015, it has issued 3,253,437 common shares in settlement of a total of $406,565 of debt. This debt settlement was previously announced in a press release on November 27, 2015, which confirmed that at the Annual and Special Meeting of Shareholders held on November 23, 2015, shareholders approved the issuance of 2,550,000 common shares to insiders related to the settlement of $328,956 of indebtedness owing to certain insiders.

The Company also announces that it has granted 100,000 share options to an insider, which are vested, and are exercisable at $0.12 for a period of two years from the date of the grant.

Following the share issuance, the Company has 73,890,509 shares outstanding. The shares issued are restricted from trading until after April 24, 2016.

About MedX

MedX, headquartered in Mississauga, Ontario, is a leading medical device company focused on skin cancer; it manufactures and distributes SIMSYS™ and MoleMate™, hand-held devices that use patented technology utilizing light and its remittance to view beneath suspicious moles and lesions in a pain free, non-invasive manner, creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. The devices are sold to physicians and clinics, as well as being deployed in drugstore settings where the images are sent remotely to dermatologists who perform a diagnosis. These products are Health Canada, FDA (US), ARTG and CE approved for use in Canada, the US, Australia and Europe. MedX also designs, manufactures and distributes quality low level laser and light therapy technologies for use in numerous medical settings, approved in major jurisdictions, providing drug free and non-invasive treatment of tissue damage and pain. For more information and a complete profile of MedX and its products visit

This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Contact Information

  • For further information:
    Robert von der Porten
    President and CEO
    MedX Health Corp.
    Phone: 905 670 4428